HemaSphere Journal

🤝Transparency notice: HemaSphere's article processing charges (APCs) will change for new manuscript submissions as of January 1, 2025. Many authors will benefit from our publisher's (@WileyOnc_Hem) extensive transformational agreement network, which could fully cover APCs. Active #EHA members will continue to be eligible for a 10% discount. Despite the adjustment, HemaSphere’s 2025 APCs remain competitively priced and will be: • Tier 1 - Articles, Review Articles, Guidelines: €2140 • Tier 2 - Perspectives, Letters: €1290 • Tier 3 - Editorials, Comments, HemaTopics, HemaPolicy: €0 #HemaSphere #OpenAccess More details here: https://bit.ly/49gBUcw

🎧Podcast Replay 2024! In the latest episode, host Dr Charles de Bock talks with Prof H. Josef Vormoor and Dr Maria Ester Bernardo, Chair and Co-Chair of EHA’s Pediatric Hematology Specialized Working Group. They discuss highlights from the EHA 2024 Congress in Madrid, including key lectures, new insights and what they could mean for clinicians, researchers, patients and their families, along with hopes and expectations for the EHA2025 Congress in Milan.  “Best of Pediatric Hematology from EHA2024”, https://bit.ly/4fziFwA, all major podcast platforms (Spotify, Apple Podcast, and more), and our YouTube channel. Listen and enjoy casual, insightful discussions about #hematology research.  We are pleased to offer HemaSphere’s full listing of publications about pediatric hematology, now in a dedicated collection. This online collection will be added to monthly 👉 https://bit.ly/4eQmptj

Few studies have explored the occurrence and prognostic implications of APBs in patients with MM treated with BCMA–specific CAR-T therapy. In this retrospective study, authors examin the frequency, isotypes, and duration of APBs, as well as their correlation with MM disease characteristics, treatment response, clinical outcomes, and immune signature in patients with relapsed/refractory MM who had received LCAR-B38M therapy at the Xi'an site of the phase 1 LEGEND-2 trial. Read more about it here 👉https://bit.ly/4gcL8Jy

Microbes support normal blood production! Authors in this recently published article report on the microbes and microbial metabolites missing from pediatric patients with antibiotic-associated neutropenia. 👉

The HemaSphere Editorial office at EHA will be closed the weeks of December 23 and 30 while we take some time to rest and gear up for 2025. Of course, our open access content remains available during this time: www.hemaspherejournal.com. Have a safe and healthy winter (or summer depending on your location) and/or festive season ahead! We can't wait to work with you come January.  Should you need immediate help with either the online manuscript or peer-review systems, feel free to contact our colleagues at Wiley: hemasphere at wiley dot com.

🎧 Podcast 2024 Replay! Listen and enjoy casual, insightful discussions about #hematology research. Authors of this recent HemaSphere published paper discovered a high-risk subgroup of pediatric T-LBL, defined by NOTCH1 gene fusions. This finding will have an important impact on newly diagnosed children with T-LBL globally, listen to two of the co-authors,  Professor Roland Kuipers and Dr Jan Loeffen discuss their findings with host Dr Charles de Bock, how they discovered them, and dreams of future developments in this HemaSphere podcast episode. NOTCH1 fusions in T‐LBL, is on our website and all major podcast platforms (Spotify, Apple Podcast, and more) including YouTube  https://bit.ly/41GUM2w You can find the referenced article, in full and open access, here on the HemaSphere website https://bit.ly/3NhzIHE

To date no AML-exclusive, non-HSPC-expressed cell-surface target molecules for AML selective immunotherapy have been identified. Time-limited combined immune-targeting of AML cells & healthy HSPCs, followed by HSCT might be a viable therapeutic approach👉

This population-based study examined COD in 20K+ CLL patients in the Netherlands between 1996 and 2020. Findings reveal CLL as the predominant COD, around 40% of relative mortality, with a declining 5-year death probability from 16.8% in 1996–2002 to 7.6% in 2010–2020. This comprehensive analysis underscores a noticeable reduction in CLL-attributed deaths and other competing causes, yet as CLL is registered as the most prevalent cause of mortality among contemporary diagnosed patients, this emphasizes the continued relevance of CLL-centric clinical strategies and research. Read about it 👉

Sci Ed Dr Charles de Bock hosts Dr Thomas Mercher & Dr Alexandre Fagnan in this episode, highlighting ETO2 activated gene transcription & how this affects erythroleukemia. The discussion traces the journey from Dr Fagnan’s PhD project (2022 #EHA Junior Grant awardee), the findings in the paper & what may lie beyond. This episode is on our website https://bit.ly/4cz0Tbr & all major podcast platforms  Listen & enjoy casual, insightful discussions about hematology research.